Prelude Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Prelude Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-300	Closed	-$23K	–	1327
2020 Q3	$23K	Sell	300 -100	-25%	-$10.1K	﹤0.01%	1302
2020 Q2	$49K	Buy	+400	New	+$39.8K	﹤0.01%	1165
2018 Q1	–	Sell	-1,000	Closed	-$89K	–	1508
2017 Q4	$89K	Sell	1,000 -500	-33%	-$43.5K	0.01%	810
2017 Q3	$140K	Buy	1,500 +1,000	+200%	+$88.4K	0.01%	761
2017 Q2	$45K	Hold	500	–	–	﹤0.01%	1034
2017 Q1	$44K	Buy	+500	New	+$44.5K	﹤0.01%	1038

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Prelude Capital Management's BMRN Position: Q2 2026 in Review

Prelude Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 5,799 shares worth $332K. The stake represents 0.02% of the portfolio and ranks #720 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in BMRN as recently as Q3 2025.

Prelude Capital Management first reported a position in BMRN in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.52M in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Prelude Capital Management held 5,799 shares of BioMarin Pharmaceuticals worth $332K as of Q2 2026.
BioMarin Pharmaceuticals was a new Prelude Capital Management position in Q2 2026.
BioMarin Pharmaceuticals made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #720 holding.
Prelude Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
Prelude Capital Management's BioMarin Pharmaceuticals position peaked at $1.52M in Q4 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.